Ultime notizie per Kura Oncology (NASDAQ:KURA) Azioni

Kura Oncology

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

Kura Oncology Inc

Kura Sushi Inc

Kura Sushi USA, Inc. - Class A Common Stock

Kura Sushi USA Inc

Kuraray Co Ltd

Piper Sandler analyst Jason Bednar maintains Solventum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) with a Neutral and raises the price target from $71 to $75.

News

Price Target

Analyst Ratings

SOLV

Piper Sandler Maintains Neutral on Solventum, Raises Price Target to $75

WIIM

MRVI

Maravai LifeSciences shares are trading lower after William Blair downgraded the stock from Outperform to Market Perform and Baird cut its price target from $10 to $9.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Guggenheim analyst Seamus Fernandez initiated coverage on Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy rating and announced a price target of $33. Cidara Therapeutics shares closed at $13.11 on Thursday. <a href="https://www.benzinga.com/quote/cdtx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Leonid Timashev initiated coverage on Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with an Outperform rating and announced a price target of $80. Cytokinetics shares closed at $55.84 on Thursday. <a href="https://www.benzinga.com/quote/cytk/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. analyst Sudan Loganathan initiated coverage on Immunome, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) with an Overweight rating and announced a price target of $30. Immunome shares closed at $12.54 on Thursday. <a href="https://www.benzinga.com/quote/imnm/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock</a>.</li>
<li>Jefferies analyst Dennis Ding initiated coverage on Inhibikase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) with a Buy rating and announced a price target of $8. Inhibikase Therapeutics shares closed at $2.78 on Thursday. <a href="https://www.benzinga.com/quote/ikt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Ben Shelley initiated coverage on Flutter Entertainment plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy rating and announced a price target of $306. Flutter Entertainment shares closed at $237.98 on Thursday. <a href="https://www.benzinga.com/quote/flut/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CYTK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="544" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-1024x544.png" alt="" class="wp-image-637640" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-1024x544.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92.png 1237w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Initiation

Pre-Market Outlook

Markets

Trading Ideas

CDTX

CYTK

FLUT

IMNM

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PARA

PARAA

Paramount Global Co-CEO Says Paramount Plus On Track To Achieve Domestic Profitability In 2025

Scotiabank analyst Patrick Colville maintains Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) with a Sector Perform and raises the price target from $85 to $87.

Scotiabank Maintains Sector Perform on Cloudflare, Raises Price Target to $87

China&#8217;s central government announced a new fiscal stimulus package worth 6 trillion yuan ($840 billion) to ease local governments&#8217; hidden debt burdens. This expansive financial program, set to be implemented by the end of 2026, marks a significant move by Beijing to address mounting economic pressures and revive growth amid global uncertainties.
The new stimulus plan, confirmed by China&#8217;s Minister of Finance Lan Fo&#8217;an, will allocate around 2 trillion yuan annually to local authorities, CNBC <a target="_blank" href="https://www.cnbc.com/2024/11/08/china-expected-to-announce-highly-anticipated-fiscal-stimulus-package.html" rel="noreferrer noopener">reports</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41812585/datadog-beats-q3-estimates-margins-show-mixed-results" rel="noreferrer noopener">Datadog Beats Q3 Estimates, Margins Show Mixed Results</a>
Additionally, central authorities will issue 800 billion yuan annually in special local government bonds, totaling 4 trillion yuan over the next five years. These measures are part of a broader strategy to reduce local hidden debt from 14.3 trillion yuan to 2.3 trillion yuan by 2028.
U.S.-listed Chinese stocks&nbsp;Alibaba Group Holding.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>),&nbsp;JD.com, Inc.&nbsp;(NASDAQ:&nbsp;JD),&nbsp;Baidu, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>),&nbsp;NIO Inc.&nbsp;(NYSE:&nbsp;NIO),&nbsp;Li Auto Inc.&nbsp;(NASDAQ:&nbsp;LI),&nbsp;and XPeng Inc.&nbsp;(NYSE:&nbsp;XPEV)&nbsp;are trading lower Friday as the stimulus failed to impress the Street <a target="_blank" href="https://www.benzinga.com/government/24/11/41806635/whats-going-on-with-us-listed-chinese-stocks-like-alibaba-jd-nio-on-thursday" rel="noreferrer noopener">which expected over</a> 10 trillion yuan ($1.39 billion) in financial support, focused on local government debt and real estate.
The financial package comes as the Chinese economy faces lingering challenges, including a real estate market slump and weaker local government revenues post-pandemic. During a press briefing, Minister Lan emphasized the urgency of addressing hidden local debts, which have ballooned to an estimated 50-60 trillion yuan ($7-8.4 trillion), according to projections by Nomura. This new initiative aims to help local governments manage interest payments, potentially saving up to 300 billion yuan annually.
China&#8217;s parliament, the National People&#8217;s Congress, is expected to formally approve the increased debt issuance quotas during its current legislative session. The move follows recent stimulus discussions led by President Xi Jinping and earlier efforts by the People&#8217;s Bank of China, which included interest rate cuts to support the economy. Market analysts anticipate heightened fiscal support after Donald Trump&#8217;s election, which may reignite trade tensions between the U.S. and China.
China aims to counter potential <a target="_blank" href="https://www.benzinga.com/government/24/11/41806635/whats-going-on-with-us-listed-chinese-stocks-like-alibaba-jd-nio-on-thursday" rel="noreferrer noopener">&#8220;Trump shocks&#8221; on trade</a> with its latest fiscal move.
After Trump&#8217;s victory, Chinese stocks declined while U.S. markets surged. During his campaign, Trump suggested boosting tariffs on Chinese imports by up to 60%. Such hikes might slash Chinese exports to the U.S. by around $200 billion and cut one percentage point from China&#8217;s GDP, according to former economic planning official Zhu Baoliang, cited by CNBC.
Price Actions:&nbsp;At the last check on Friday, BABA stock is down 3.28% at $96.86 premarket. JD is down 3.44%, BIDU is down 2.20%, NIO is down 2.26%, LI is down 4.96%, and XPEV is down 2.74%.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41812311/appian-projects-positive-adjusted-ebitda-boasts-strong-subscription-revenue-in-q3" target="_blank" rel="noreferrer noopener">Appian Projects Positive Adjusted EBITDA, Boasts Strong Subscription Revenue In Q3</a></li>
</ul>
Photo Via Shutterstock

Government

Regulations

Media

BABA

BIDU

China's Stimulus Plan Not Enough To Ignite Stocks

Kentucky Governor <a href="https://www.benzinga.com/topic/andy-beshear">Andy Beshear</a> (D) hailed the outcome of Tuesday's election as a decisive statement on medical cannabis reform. In an election process that had bipartisan and widespread support, voters in over 100 cities and counties across the state approved local measures to permit medical marijuana businesses in their towns and jurisdictions.
Beshear, <a href="https://www.benzinga.com/markets/cannabis/23/03/31612072/kentucky-becomes-38th-state-to-legalize-medical-marijuana-as-gov-beshear-signs-bill-into-law">who signed a medical marijuana legalization bill </a>into law last year, declared that the results confirm what many already believed: Kentuckians support cannabis reform.
"This signals what we have known for a long time, which is that the jury is no longer out on medical cannabis," Beshear <a href="https://www.kentucky.gov/Pages/Activity-stream.aspx?n=GovernorBeshear&amp;prId=2333">said</a> in his weekly new conference Thursday. "Kentuckians want their families, friends and neighbors who have serious medical conditions &#8211; like cancer, multiple sclerosis or PTSD &#8211; to have safe and affordable access. We are keeping our promise to make sure they will."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41775201/cannabis-reform-stumbles-in-2024-elections-a-state-by-state-breakdown-as-stocks-take-a-hit">Cannabis Reform Stumbles In 2024 Elections: A State-By-State Breakdown As Stocks Take A Hit</a>
All 53 cities and 53 counties presented with medical cannabis measures in Kentucky approved them, with over 340,000 votes cast in favor. This continues a trend in the state where more than 40 cities have already authorized marijuana businesses and only 20 jurisdictions have opted to ban them.
"We saw overwhelming support at the polls for our new system of medical cannabis," Beshear said, noting the uniform wins for the measures. "In every single place that medical cannabis was put on the ballot, it won &#8211; meaning citizens of every part of Kentucky said that it is time and they want to see this option in their community."
Of the state&#8217;s 106 ballot measures, no counties or cities opted to bar medical marijuana businesses from operating in their borders, according to data <a href="https://x.com/Hicks_JustinM/status/1854016544038158830">compiled </a>by Louisville Public Media&#8217;s Justin Hicks at WFPL News who <a href="https://x.com/WFPLNews">noted </a>that "every single county and every single city voted to approve medical cannabis businesses."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">According to my scraping of Kentucky local elections, &#x2A;every single county&#x2A; and &#x2A;every single city&#x2A; voted to approve medical cannabis businesses. <a href="https://t.co/FAVRN0HghV">pic.twitter.com/FAVRN0HghV</a>
&mdash; Justin Hicks (@Hicks_JustinM) <a href="https://twitter.com/Hicks_JustinM/status/1854016544038158830?ref_src=twsrc%5Etfw">November 6, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Kentucky stood apart in this year&#8217;s elections as <a href="https://www.benzinga.com/markets/cannabis/24/11/41775201/cannabis-reform-stumbles-in-2024-elections-a-state-by-state-breakdown-as-stocks-take-a-hit">cannabis reform ballots failed </a>in North Dakota, South Dakota and Florida.
Kentucky&#8217;s new medical marijuana law will come into effect in January 2025. Preparations by the Office of Medical Cannabis (OCM) include <a href="https://www.benzinga.com/markets/cannabis/24/10/41608654/kentucky-and-delaware-held-cannabis-licensing-lotteries-ushering-in-new-regulated-marketshttps://www.benzinga.com/markets/cannabis/24/10/41608654/kentucky-and-delaware-held-cannabis-licensing-lotteries-ushering-in-new-regulated-markets">recent lotteries for approving</a> cultivators, processors and testing facilities, with a dispensary lottery scheduled for Dec. 16. Starting Dec. 1, physicians will be able to issue medical marijuana recommendations, and patients can begin applying for their cannabis cards on Jan. 1.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41829368/overdose-crisis-in-shadows-of-elections-as-black-indigenous-americans-deaths-rise">Overdose Crisis In Shadows Of Elections As Black, Indigenous Americans Deaths Rise</a></li>
</ul>
Government photo&nbsp;of Andy Beshear

Cannabis

Health Care

Legal

Kentucky Gov. Beshear: 'The Jury Is No Longer Out,' Kentuckians Want Medical Cannabis

Piper Sandler analyst Peter Keith reiterates YETI Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YETI#NYSE">YETI</a>) with a Overweight and lowers the price target from $55 to $54.

Reiteration

YETI

Piper Sandler Reiterates Overweight on YETI Holdings, Lowers Price Target to $54

Scotiabank analyst Konark Gupta maintains Chorus Aviation (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CHR#TSX">CHR</a>) with a Sector Perform and raises the price target from C$3.25 to C$3.4.

TSX:CHR

Scotiabank Maintains Sector Perform on Chorus Aviation, Raises Price Target to C$3.4

FTRE

Fortrea shares are trading higher after the company issued FY24 revenue guidance above estimates.

Piper Sandler analyst Thomas Champion reiterates Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) with a Overweight and lowers the price target from $45 to $41.

PINS

Piper Sandler Reiterates Overweight on Pinterest, Lowers Price Target to $41

Piper Sandler analyst Alexander Potter maintains Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) with a Overweight and lowers the price target from $21 to $19.

RIVN

Piper Sandler Maintains Overweight on Rivian Automotive, Lowers Price Target to $19

Scotiabank analyst Tanya Jakusconek maintains Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>) with a Sector Outperform and lowers the price target from $25 to $24.

GOLD

Scotiabank Maintains Sector Outperform on Barrick Gold, Lowers Price Target to $24

Piper Sandler analyst Thomas Champion maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Neutral and raises the price target from $125 to $145.

ABNB

Piper Sandler Maintains Neutral on Airbnb, Raises Price Target to $145

Scotiabank analyst Maher Yaghi maintains BCE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCE#TSX">BCE</a>) with a Sector Perform and lowers the price target from C$47.5 to C$45.

TSX:BCE

Scotiabank Maintains Sector Perform on BCE, Lowers Price Target to C$45

The Fed's widely anticipated 25 basis point rate cut on Thursday left investors with a sense of relief – but not certainty. According to JPMorgan analyst Maia G Crook. <a href="https://www.benzinga.com/federal-reserve">While Federal Reserve</a> Chair Jerome Powell acknowledged the U.S. economy's resilience, inflation remains a nagging issue.
In the post-meeting press conference, Powell highlighted key growth drivers, including robust consumer spending and a solid labor market.
However, he attributed persistent inflation, or the &#8220;elephant in the conference room,&#8221; largely to lagging pressures, such as shelter and insurance costs, underscoring that the fight against rising prices is far from over.
She notes that while Powell signaled some progress, he avoided providing a clear path forward, emphasizing the Fed's "data-dependent" approach.
Read Also: <a href="https://www.benzinga.com/news/large-cap/24/11/41826586/wall-street-closes-at-record-highs-after-reassurance-from-powell-magnificent-7-hit-17-trillion-tre">Wall Street Hits Record Highs After Powell&#8217;s Speech, Lifts Magnificent 7 Stocks To $17 Trillion In Historic Trading</a>
<h2 class="wp-block-heading">What's Next For December?</h2>
Crook expects another 25 basis point cut in December, followed by quarterly cuts in 2025, but warns the Fed might hold off if the inflation rate doesn't continue to ease. With Powell leaving options open, she suggests the Fed's caution reflects a genuine concern over stubborn inflation that could delay the easing path investors hope for.
ETFs such as the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), the iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>) and the Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) provide exposure to broad market U.S. equities.
<h2 class="wp-block-heading">Politics In The Background</h2>
When asked about the impact of the recent election, Powell stressed that policy decisions will remain apolitical, emphasizing that he would not step down if asked and can't legally be removed from his position. Crook notes that Powell's clarification here reaffirms the Fed's independence, reassuring markets wary of potential political pressures.
She sees the Fed as ready for a December cut, but with inflation still looming large, investors should remain cautious. As Powell sidesteps firm guidance, the Fed's data-driven approach means a slower path is on the table if inflation remains stubborn.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41823887/powell-dismisses-talk-of-resignation-after-trump-victory-says-policy-is-still-res">Powell Dismisses Talk Of Resignation After Trump Victory, Says &#8216;Policy Is Still Restrictive&#8217;</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Macro Economic Events

Economics

Federal Reserve

Fed Cuts Interest Rates, But Inflation Remains Elephant In The Room

Offerings

NMHI

Nature's Miracle Holding Prices Public Offering For Aggregate Gross Proceeds Of $3M

Piper Sandler analyst Clarke Jeffries maintains Amplitude (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPL#NASDAQ">AMPL</a>) with a Neutral and raises the price target from $9 to $11.

AMPL

Piper Sandler Maintains Neutral on Amplitude, Raises Price Target to $11

EHang Holdings' EH216-S Pilotless eVTOL Completes Debut Passenger Flights In Thailand

GCM Grosvenor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCMG#NASDAQ">GCMG</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.15 by 6.67 percent. This is a 6.67 percent increase over earnings of $0.15 per share from the same period last year. The company reported quarterly sales of $122.93 million which missed the analyst consensus estimate of $123.80 million by 0.70 percent. This is a 1.00 percent increase over sales of $121.71 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

GCMG

GCM Grosvenor Q3 Adj $0.16 Beats $0.15 Estimate, Sales $122.93M Miss $123.80M Estimate

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Verizon downgraded, Canadian Pacific upgraded: Wall Street's top analyst calls

UBS launches SMID cap biotechs with cancer, autoimmunity in focus

Kura Oncology (KURA) announced that two abstracts highlighting clinical data from the KOMET-007 combination trial of ziftomenib, the Company's pote...

Kura Oncology to present updated data from KOMET-007 trial

In a report released yesterday, Charles Zhu from LifeSci Capital maintained a Buy rating on Kura Oncology (KURA – Research Report), with a price ta...

Buy Rating for Kura Oncology Supported by Promising Ziftomenib Data and Strategic Drug Development

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Kura Oncology (KURA – Research Report). The associated price target...

Promising Outlook for Kura Oncology: Positive Phase 1 KOMET-007 Trial Results Support Buy Rating

Kura Oncology Q3 2024 Earnings Preview

Kura Oncology GAAP EPS of -$0.63 in-line

TD Cowen analyst Phil Nadeau has maintained their bullish stance on KURA stock, giving a Buy rating yesterday. Phil Nadeau has given his Buy rating...

Phil Nadeau Affirms Buy Rating on Kura Oncology Thanks to Promising Clinical Trials and Robust Financial Position

Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Kura Oncology (KURA – Research Report) yesterday and set a price targe...

Kura Oncology Receives Buy Rating: Promising Developments in NPM1m AML Treatment and Attractive Valuation

In a report released today, George Farmer from Scotiabank maintained a Hold rating on Kura Oncology (KURA – Research Report), with a price target o...

Scotiabank Sticks to Their Hold Rating for Kura Oncology (KURA)

BPMC

CATX

CGEM

CGON

HAFC

IDYA

IMCR

IOVA

JANX

KURA

MRUS

NRIX

NUVL

SIRI

SNDX

Press Releases

Kura Oncology Reports Second Quarter 2024 Financial Results

Kura Oncology to Participate in Cantor Global Healthcare Conference

Management

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

General

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)

Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

Kura Oncology to Report Third Quarter 2024 Financial Results

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

Comments

Kura Oncology

Notizie

Ultime notizie per Kura Oncology (NASDAQ:KURA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO